Members of the bacterial Shiga toxin family consist of a single A subunit that is non-covalently associated with a pentamer of B subunits. These toxins bind to receptors on susceptible mammalian cells and enter the cells by endocytic uptake. During cell entry, the 32 kDa A subunit is cleaved by the membraneanchored protease furin to generate a catalytically active, 27.5 kDa A, fragment and a 4 5 kDa A, fragment. Previous studies have shown that mutating the furin site to prevent cleavage did not significantly affect toxin potency, suggesting that cleavage is not required for toxin activity. Here it is confirmed that preventing cleavage a t the usual processing site does not prevent proteolytic processing of the Escherichia coli Shiga-like toxin-I A subunit. However, simultaneous mutation of both the primary furinrecognition site and a nearby putative furin cleavage site did prevent intracellular processing of the A subunit. Comparison of the cytotoxicities of purified recombinant toxins t o cultured mammalian cells demonstrated that even on prolonged incubation with toxin, the unprocessed mutant was 60-fold less toxic than the wild-type protein or other mutants still capable of being proteolytically processed during cell entry.
INTRODUCTION
The Shiga toxin family includes Shiga toxin itself (ST, from Shigella dysenteriae) and Shiga-like toxins-1 and -2 (SLT-1 and SLT-2, from enterohaemorrhagic Escherichia coli) (Tesh & O'Brien, 1991) . All of these toxins consist of an enzymic 32 kDa A subunit, which is an RNA N-glycosidase that removes a specific adenine into a 27.5 kDa A, fragment, which has the RNA Nglycosidase activity, and a 4.5 kDa A, fragment. Several other bacterial toxins, including diphtheria toxin and Pseudomonas exotoxin A, must undergo an equivalent cleavage by furin during cell entry (Gordon & Leppla, 1994) before the catalytically active polypeptide fragment can be translocated into the cytosol, where the rRNA substrates are located.
residue from 28s rRNA (Endo et al., 1988) , noncovalently associated with a pentamer of 7.7 kDa B subunits, which bind the toxin to plasma-membrane globotriosyl ceramides present on susceptible mammalian cells (Lindberg et al., 1987) . The toxin A subunits contain two cysteines joined by a disulphide bond. The loop between the disulphide-linked cysteines contains the sequence Arg-X-X-Arg, which is readily cleaved in uitro by trypsin (Olsnes et al., 1981) and, following toxin entry into mammalian cells, by the ubiquitous protease furin (Garred et al., 1995a) . Cleavage splits the A subunit It has been reported that proteolytic cleavage increases the enzymic activity of ST between 10- (Olsnes et al., 1981) and 40-fold (Brown et al., 1980) , but proteolytic nicking of SLT-1 in uitro did not increase its toxicity to mammalian cells (Kongmuang et al., 1988) . It has also been shown that preventing cleavage at the furinsensitive site, using site-directed mutagenesis to remove the Arg-X-X-Arg target sequence, has no significant effect on the toxicity of ST (Garred et al., 1995b) , SLT-1 (Burgess & Roberts, 1993) or SLT-2 (Samuel & Gordon, 1994) incubation times. However, the ST study (Garred et al., 1995b ) also found that cells were able to cleave both wild-type toxin and the mutants, although the cellular locations of these cleavage steps appeared to differ. 
Apparently, ST can be cleaved at an alternative site close to the primary cleavage site for furin (Garred et al., 1995b) . O n the basis of this observation, it seems possible that mutant SLTs might also undergo proteolytic cleavage at a second distinct site, and the conclusion that proteolytic processing is not essential for cytotoxicity (Garred et al., 1995b; Burgess & Roberts, 1993; Samuel & Gordon, 1994) might not be valid. In order to test this, we have produced a recombinant SLT-1 mutant that does not undergo any apparent proteolytic cleavage during cell entry. Although this mutant retains some potency after prolonged incubation with cells, it is significantly less toxic than either wild-type toxin or the furin-site mutant, indicating that proteolytic processing to release a catalytically active fragment is required for optimal cytotoxicity .
METHODS
Bacterial strain, bacteriophage and plasmids. E. coli JMl05
[supE endA sbcBl5 hsdR4 rps thi A(lac-proAB) F'(traD36 proAB+ lacIqllacZAM15)] was used for all genetic manipulations and the expression of recombinant proteins. M13mp18 was used for the production of single-stranded DNA for sequencing and site-directed mutagenesis. The coding region of SLT-1, including the Shine-Dalgarno sequence, was amplified by PCR from E. coli 0157:H7 cell paste using oligonucleotide primers designed to incorporate a PstI site at the 5' end and an EcoRI site at the 3' end. The DNA oligonucleotides used were 5' GCTAGAATTCTCAACGAAAAATAACTT 3' and 5' CGGAACTGCAGCAAGGAGTATTGTGTAATAT 3'. The resulting fragment was cloned into the PstIIEcoRI sites of M13mp18. After mutagenesis, PstI-EcoRI fragments encoding the entire wild-type SLT-1 operon or mutant A subunit containing the appropriate amino acid substitutions were cloned into the PstI/EcoRI site of pUC19 to create the expression plasmids pSLTwt, pSLT1, pSLT2, pSLT3 and pSLT4. Amino acid substitutions in the various mutants are shown in Table 1 . Sitedirected mutagenesis. The T7-Gen in vitro mutagenesis system (United States Biochemical) was used for the preparation of mutated M13 DNA. Mutagenic oligonucleotides, 3' to generate mutant SLTP3, and 5' 1046GAC-TC~GTTGGTGTAGGAGGAATTTCTT~O~~ 3' to generate mutant SLTP4. Mismatched bases are underlined and the numbering denotes the position at which the primer anneals in the sequence published by Calderwood et al. (1987) .
Purification of recombinant toxin. SLT-1 was prepared from periplasmic extracts of E. coli. JMlO5 transformed with the wild-type expression plasmid pSLTwt or one of the mutantencoding plasmids described above. Cells were grown in Luria broth supplemented with 100 pg ampicillin ml-l to an OD,,, of 0.6 (measured with a Shimadzu UV-160 spectrophotometer). Expression was induced by the addition of IPTG (1 m M final concentration) and allowed to proceed for 3 h. Cells were harvested by centrifugation (10 min at 7500 g), washed in 600 mM sucrose, 300 m M Tris/HCl (pH 8*0), 1 m M EDTA and 0.5 m M MgCl,, and resuspended in 1 m M Tris/HCl, p H 7.5. After incubation on ice for 10 min, cell debris was removed by centrifugation (15 min at 15 000 g). The supernatant was filter-sterilized by passage through a 0.2 pm filter and applied to a 6 ml globotriose-Sepharose affinity column (Muller et al., 1998) equilibrated with 0-5 M NaCl in phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 m M KC1, 10 m M Na,HPO,, 1.8 m M KH,PO,, pH 7.4). The column was washed with 40 vols 0.5 M NaCl in PBS prior to eluting SLT-1 with 6 M guanidine.HC1. Fractions of 1 ml were collected and immediately dialysed against PBS to remove the denaturant.
Quantification and activity of recombinant proteins. Purified recombinant toxins were quantified from their A,,, value; an absorption coefficient of 0.984 was calculated for SLT-1 from its primary sequence. Quantification was confirmed by comparison of known amounts of pure SLT-1 on silver-stained polyacrylamide gels. The activity of the recombinant proteins was determined by assessing their specific ability to depurinate 28s RNA of ribosomes isolated from untreated rabbit reticulocyte lysates (Promega). Toxins were incubated for 30 min at 30 "C with 30 pg purified ribosomes in a reaction volume of 30 pl. rRNA was isolated and the extent of depurination was determined by using the aniline assay as described previously (May et al., 1989) .
In wiwo proteolytic cleavage of toxins. Recombinant SLT-1 and the SLT-1 mutants were labelled with 1251 by the Iodogen method to a specific activity of approximately 25 000 c.p.m. ng-l. Vero (African green monkey kidney) cells were grown in six-well plates in Dulbecco's modification of Eagle's medium (DMEM; Gibco-BRL) containing 5 '/o foetal calf serum and 2 m M glutamine, to a density of approximately 5 x lo5 cells per well. After washing with PBS, 100 ng 1251-labelled toxin ml-l was added to each well in 1.5 ml DMEM and the cells were incubated for various time periods. Following incubation, the cells were washed three times with PBS and lysed in cell-lysis buffer supplemented with protease inhibitors (1 '/o Triton X-100, 150 m M NaC1, 50 m M Tris/HCl, pH 7-4, 210 pM leupeptin, 80 pM chymostatin, 6 pM elastinol, 1.6 pM pepstatin, 0.3 pM aprotinin, 1 m M PMSF and 1 mM EDTA). Cell debris was removed by centrifugation (5 min at 7500 g Laemmli (1970) . '"I-labelled toxin was visualized by fixing the gels in 10% acetic acid/40 '/o methanol followed by treatment with Amplify (Amersham) for 15 min. Preflashed Fuji X-ray film was exposed to dried gels at -70 "C.
RESULTS

Construction and expression of mutant toxins
The SLT-1 mutants generated during this study are listed in Table 1 . In mutant SLTP1, Arg,,, and Arg,,, of the furin target site were each changed to Gly. An earlier report suggested that, based on Edman degradation, SLT-1 A subunit was nicked between Ala,,, and Ser254, present in the disulphide loop, to generate the A, and A, fragments (Takao et al., 1988) . Accordingly, this Ala-Ser pair and a second pair also present in the disulphide loop, Ala,,, and Ser,,,, were changed to Gly and Ala, respectively, to generate mutant SLTP2. Mutant SLTP3 contained a combination of the mutations present in SLTPl and SLTP2. SLT-1 contains a second putative furin cleavage site (Arg,,,-Val-Gly-Arg,,,) outside the disulphide loop. Thus Arg,,, and Arg,,, were both changed to Gly in the background of mutant SLTP3 to generate mutant SLTP4.
Recombinant wild-type SLT-1 and the four mutants listed in Table 1 were expressed in E. coli and purified to homogeneity by affinity chromatography on a column of immobilized synthetic globotriose (Muller et al., 1998) . Fig. 1 shows the results of a typical purification.
Biological activity of recombinant toxins
The recombinant proteins were catalytically active. The N-glycosidase activity removes a specific adenine residue from a highly conserved loop close to the 3' end of 28s E. coli periplasmic fraction was passed down an immobilized globotriose column, unbound material was removed by washing and bound toxin was eluted with 6 M guanidine.HC1. Proteins in the various fractions were separated on a 15 % SDSpolyacrylamide gel and stained with Coomassie blue. Lanes: 1, molecular mass markers; 2, total periplasmic fraction from cells expressing wild-type SLT-1; 3, fraction of the periplasmic fraction that did not bind to the column; 4, purified wild-type SLT-1; 5, SLTP1; 6, SLTP2; 7, SLTP3; 8, SLTP4. Rabbit reticulocyte ribosomes were incubated with toxin for 30 min a t 30 "C. rRNA was isolated, treated with aniline, separated on a 1.2% denaturing formamide gel and transferred to nitrocellulose. Northern blot analysis was performed using an end-labelled oligonucleotide probe complementary to a region of 285 rRNA downstream of the depurination site. The bottom arrow (aniline fragment) indicates the -400 base RNA fragment diagnostic for depurination. Lanes: 1-3, RNA from ribosomes treated with 1000, 100 or 10 ng wild-type SLT-1; 4-6, 7-9, 10-12 and 13-15, RNA from ribosomes treated with the corresponding amounts of SLTP1, SLTP2, SLTP3 and SLTP4, respectively.
ribonucleotides from 28s rRNA that is diagnostic of SLT-1 N-glycosidase activity. Rabbit reticulocyte ribosomes were incubated with different amounts of the purified toxins and the rRNA was isolated and treated with acetic-aniline to hydrolyse depurinated rRNA before being separated on denaturing formamide gels. The presence of the short, diagnostic RNA fragment on gels of total rRNA from toxin-treated ribosomes was confirmed by Northern blotting using a radiolabelled DNA probe complementary to a sequence present in the released RNA fragment. As shown in Fig. 2 
the fragment with a concomitant decrease in the signal for unmodified 28s rRNA. Qualitatively, at least, the proteins appeared to be very similar in their abilities to depurinate rRNA. Subsequent work showed that the stability and properties of mutant SLTP2 were indistinguishable from those of wild-type SLT-1. SLTP2 was therefore not analysed further in the present study. 
Proteolytic processing following entry into mammalian cells
In order to determine whether the various toxin mutants were proteolytically cleaved intracellularly, the purified toxins were labelled with 1251 and incubated with SLTreceptor-bearing Vero cells. After various incubation times, the cells were washed to remove extracellular toxin and lysed, total protein was precipitated and separated electrophoretically and toxin was visualized by fluorography. As shown in Fig. 3 , wild-type SLT-1 and mutants SLTPl and SLTP3 were all processed to generate the A, fragment, but mutant SLTP4 was apparently resistant to cellular proteolysis. The extent of cleavage of the A subunit to the A, fragment was quantified by scanning densitometry and is shown in Fig. 4 . The resistance of mutant SLTP4 to proteolytic cleavage indicates that the cleavage seen here for mutants SLTPl and SLTP3, and that reported elsewhere for a mutant in which the furin site in the disulphide loop had been disrupted (Garred et al., 1995b) , most likely occurs at the second putative furin site, Arg,,,-Val-Gly-Arg,,,.
Cytotoxicity to mammalian cells
The cytotoxicities of the wild-type and mutant SLTs were determined by measuring the capacity of Vero cells to synthesize protein after a 6 h incubation with a range of concentrations of toxin (Fig. 5) . Wild-type toxin and the mutants that could be cleaved proteolytically intracellularly were of comparable cytotoxicity, while mutant SLTP4 was clearly less toxic. The IC,, (the toxin concentration that caused a 50% decrease in total protein synthesis in comparison with that of untreated control cells) for SLTP4 was 360 pg ml-', around 60-fold greater than that for wild-type SLT-1. When cells were incubated with toxin for 3 h, wild-type SLT appeared to be more toxic than mutants SLTPl and SLTP3 (data not shown), indicating presumably that cleavage at the alternative site was less efficient than cleavage at the normal furin site. Incubating the cells with toxins for periods greater than 6 h gave toxicity profiles identical to those observed after 6 h (Fig. 5) . reduced toxicity in the absence of proteolytic cleavage (mutant SLTP4) is unclear, particularly as the catalytic activity of mutant SLTP4 seems to be very similar to that of wild-type SLT-1 (Fig. 2 , compare lanes 10-12 with lanes 1-3).
DISCUSSION
In this study, we have investigated whether proteolytic processing of the catalytic A subunit of members of the Shiga toxin family, exemplified here by SLT-1 from E. coli, is required for toxicity to mammalian cells.
Previous work has clearly established that proteolytic processing of the A subunit into A, and A, fragments does occur following toxin entry into mammalian cells (Garred et al., 1995b) . Processing is achieved through the action of furin, which recognizes the sequence Arg-X-X-Arg (Molloy et al., 1992) , a sequence found within a disulphide loop in all members of the Shiga toxin family. Many bacterial toxins that modify target substrates catalytically in the cytosol of mammalian cells require proteolytic cleavage in order to act (Gordon & Leppla, 1994) . Some of these toxins, such as diphtheria toxin (Drazin et al., 1971) and Pseudomonas exotoxin A (Vasil et al., 1977) , are synthesized as catalytically inactive, non-toxic proprotein precursors in which the catalytic and cell-binding subunits are present initially as part of a single polypeptide. When the inactive, native proforms of either diphtheria toxin or Pseudomonas exotoxin A enter mammalian cells, proteolytic cleavage releases the A fragment from the cell-binding B fragment and thereby activates these toxins. Once again, it is now clear that furin is the cellular endoprotease responsible for this activation. Both diphtheria toxin and Pseudomonas exotoxin A contain an Arg-X-X-Arg sequence within a disulphide loop and both are cleaved by furin in vitro (Chiron et al., 1994) . Mutating the cleavage site so that it is no longer recognized by furin abolished cytotoxicity (Williams et al., 1990; Ogata et al., 1990) . It has also been shown that cells lacking furin are resistant to both diphtheria toxin and Pseudomonas exotoxin A, but sensitivity can be restored by transfecting a cDNA encoding furin (Moehring et al., 1993; Tsuneoka et al., 1993 ).
Clearly, toxins in which the catalytic and cell-binding polypeptides are present initially in a single precursor require proteolytic processing by furin to release and thereby activate the catalytic A fragment. The Shiga toxins are somewhat different, however, in that the A subunit is not covalently attached to the cell-binding peptides of the B-subunit pentamer. Cells lacking furin remain sensitive to ST, although transfecting the furin gene increased both the rate of cleavage of endocytosed toxin and sensitivity to it (Garred et al., 1995a) . Further, abolishing the furin cleavage site by mutation in the disulphide loops of ST (Garred et al., 1995b) , SLT-1 (Burgess & Roberts, 1993) and SLT-2 (Samuel & Gordon, 1994) does not abolish cytotoxicity. However, proteolytic processing may still be essential and, if a second cleavage site remains available, this could account for the toxicity of the mutants analysed thus far. In the present study, it has been shown that eliminating the primary furin-recognition site of SLT-1 (mutant SLTP1) does not prevent intracellular cleavage (Fig. 3) , confirming an earlier observation made in the case of ST (Garred et al., 1995b) . On the basis of these data, mutant SLTP4 was produced, in which an additional putative furin cleavage site (Arg,,,-Val-Gly-Arg,,,) was mutated. It should be noted that the alternative processing site reported for ST by Garred et al. (1995b) lay within the disulphide loop, since reduction was required to release the A,-sized fragment from the processed A subunit. Processing at this alternative site appeared to occur in the cytosol since, in contrast to the wild-type protein, it could be prevented by treating the cells with a membrane-permeable inhibitor of the cytosolic enzyme calpain (Garred et al., 1995b) . It is possible that this ST mutant could have been cleaved at one of the Ala-Ser pairs, present in the disulphide loop, which had earlier been implicated as potential processing sites (Takao et al., 1988) . In mutant SLTP3 produced in the present study, both Ala-Ser pairs as well as the primary furin site within the disulphide loop had been removed. This suggested that the processing observed for SLTP3 (Fig.  3) occurred at a site outside the disulphide loop, a contention supported by the finding that processing of mutant SLTP4 was abolished by an additional mutation introduced into the sequence outside the loop. Although mutant SLTP4 did not appear to be processed during cell entry (Figs 3 and 4) even when endocytosed toxin was incubated with cells for 6 h, it did remain cytotoxic upon prolonged (6 h) incubation with cells, albeit -60-fold less toxic than wild-type SLT-1 (Fig. 5 ) . At present, it is IP: 54.70.40.11
On: Thu, 03 Jan 2019 01:32:08 N . L E A , J . M . L O K D a n d L . M . R O B E R T S not clear why some form of proteolytic processing is necessary for optimal cytotoxicity. It is possible that the uncleaved A, moiety reduces the efficiency of A subunit membrane translocation into the cytosol, or somehow partially destabilizes it or enhances the rate of its intracellular degradation, effectively reducing the concentration of functional toxin in the cytosol. However, the most likely explanation for the need for processing for optimal activity cotnes from the X-ray crystallographic structure of ST (Fraser et al., 1994) , which provides a clear structural basis for this requirement. In the uncleaved A subunit, residues 258-262 of A, lie adjacent to the active-site cleft of A, and the side chain of Met,,,, protrudes into the active site itself. This structural feature may explain why removal of the A, portion of ST/SLT, including residue 260, results in increased catalytic activity. In conclusion, while it is clear that a form of SLT-1 that does not undergo any observable protcolytic cleavage during cell entry (mutant SLTP4) remains cytotoxic, cleavage at either the preferred furin site or an adjacent site is required for SLT-1 to exhibit maximal toxicity towards mammalian cells.
